Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
Identifieur interne : 000A17 ( PubMed/Corpus ); précédent : 000A16; suivant : 000A18Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
Auteurs : Luis De La Cruz-Merino ; Lorenza Di Guardo ; Jean-Jacques Grob ; Alfredo Venosa ; James Larkin ; Grant A. Mcarthur ; Antoni Ribas ; Paolo A. Ascierto ; Jeffrey T R. Evans ; Antonio Gomez-Escobar ; Giulio Barteselli ; Susan Eng ; Jessie J. Hsu ; Anne Uyei ; Brigitte DrénoSource :
- Journal of translational medicine [ 1479-5876 ] ; 2017.
Abstract
Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF (V600)-mutated melanoma treated in the Phase III coBRIM study.
DOI: 10.1186/s12967-017-1246-0
PubMed: 28646893
Links to Exploration step
pubmed:28646893Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.</title><author><name sortKey="De La Cruz Merino, Luis" sort="De La Cruz Merino, Luis" uniqKey="De La Cruz Merino L" first="Luis" last="De La Cruz-Merino">Luis De La Cruz-Merino</name><affiliation><nlm:affiliation>Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani 3, 41071, Seville, Spain. lucme12@yahoo.es.</nlm:affiliation></affiliation></author><author><name sortKey="Di Guardo, Lorenza" sort="Di Guardo, Lorenza" uniqKey="Di Guardo L" first="Lorenza" last="Di Guardo">Lorenza Di Guardo</name><affiliation><nlm:affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation><nlm:affiliation>Aix-Marseille University, Hôpital de la Timone, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Venosa, Alfredo" sort="Venosa, Alfredo" uniqKey="Venosa A" first="Alfredo" last="Venosa">Alfredo Venosa</name><affiliation><nlm:affiliation>Ospedale Monaldi, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation><nlm:affiliation>Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation><nlm:affiliation>Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation><nlm:affiliation>Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Evans, Jeffrey T R" sort="Evans, Jeffrey T R" uniqKey="Evans J" first="Jeffrey T R" last="Evans">Jeffrey T R. Evans</name><affiliation><nlm:affiliation>Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gomez Escobar, Antonio" sort="Gomez Escobar, Antonio" uniqKey="Gomez Escobar A" first="Antonio" last="Gomez-Escobar">Antonio Gomez-Escobar</name><affiliation><nlm:affiliation>Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani 3, 41071, Seville, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Barteselli, Giulio" sort="Barteselli, Giulio" uniqKey="Barteselli G" first="Giulio" last="Barteselli">Giulio Barteselli</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Eng, Susan" sort="Eng, Susan" uniqKey="Eng S" first="Susan" last="Eng">Susan Eng</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hsu, Jessie J" sort="Hsu, Jessie J" uniqKey="Hsu J" first="Jessie J" last="Hsu">Jessie J. Hsu</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Uyei, Anne" sort="Uyei, Anne" uniqKey="Uyei A" first="Anne" last="Uyei">Anne Uyei</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dréno">Brigitte Dréno</name><affiliation><nlm:affiliation>Nantes University, Nantes, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28646893</idno><idno type="pmid">28646893</idno><idno type="doi">10.1186/s12967-017-1246-0</idno><idno type="wicri:Area/PubMed/Corpus">000A17</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A17</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.</title><author><name sortKey="De La Cruz Merino, Luis" sort="De La Cruz Merino, Luis" uniqKey="De La Cruz Merino L" first="Luis" last="De La Cruz-Merino">Luis De La Cruz-Merino</name><affiliation><nlm:affiliation>Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani 3, 41071, Seville, Spain. lucme12@yahoo.es.</nlm:affiliation></affiliation></author><author><name sortKey="Di Guardo, Lorenza" sort="Di Guardo, Lorenza" uniqKey="Di Guardo L" first="Lorenza" last="Di Guardo">Lorenza Di Guardo</name><affiliation><nlm:affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation><nlm:affiliation>Aix-Marseille University, Hôpital de la Timone, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Venosa, Alfredo" sort="Venosa, Alfredo" uniqKey="Venosa A" first="Alfredo" last="Venosa">Alfredo Venosa</name><affiliation><nlm:affiliation>Ospedale Monaldi, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation><nlm:affiliation>Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation><nlm:affiliation>Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation><nlm:affiliation>Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Evans, Jeffrey T R" sort="Evans, Jeffrey T R" uniqKey="Evans J" first="Jeffrey T R" last="Evans">Jeffrey T R. Evans</name><affiliation><nlm:affiliation>Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gomez Escobar, Antonio" sort="Gomez Escobar, Antonio" uniqKey="Gomez Escobar A" first="Antonio" last="Gomez-Escobar">Antonio Gomez-Escobar</name><affiliation><nlm:affiliation>Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani 3, 41071, Seville, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Barteselli, Giulio" sort="Barteselli, Giulio" uniqKey="Barteselli G" first="Giulio" last="Barteselli">Giulio Barteselli</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Eng, Susan" sort="Eng, Susan" uniqKey="Eng S" first="Susan" last="Eng">Susan Eng</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hsu, Jessie J" sort="Hsu, Jessie J" uniqKey="Hsu J" first="Jessie J" last="Hsu">Jessie J. Hsu</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Uyei, Anne" sort="Uyei, Anne" uniqKey="Uyei A" first="Anne" last="Uyei">Anne Uyei</name><affiliation><nlm:affiliation>Genentech, Inc., South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dréno">Brigitte Dréno</name><affiliation><nlm:affiliation>Nantes University, Nantes, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of translational medicine</title><idno type="eISSN">1479-5876</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF (V600)-mutated melanoma treated in the Phase III coBRIM study.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28646893</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>25</Day></DateCreated><DateRevised><Year>2017</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.</ArticleTitle><Pagination><MedlinePgn>146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-017-1246-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF (V600)-mutated melanoma treated in the Phase III coBRIM study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247) or vemurafenib (n = 246). All patients underwent prospective ophthalmic examinations at screening, at regular intervals during the study, and whenever ocular symptoms developed. Patients with serous retinopathy were identified in the study database using a group of relevant and synonymous adverse event terms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-six serous retinopathy events were reported in 70 patients (79 events in 63 cobimetinib and vemurafenib-treated patients vs seven events in seven vemurafenib-treated patients). Most patients with serous retinopathy identified by ophthalmic examination had no symptoms or had mild symptoms, among them reduced visual acuity, blurred vision, dyschromatopsia, and photophobia. Serous retinopathy usually occurred early during cobimetinib and vemurafenib treatment; median time to onset was 1.0 month. Most events were managed by observation and continuation of cobimetinib without dose modification and resolved or were resolving by the data cutoff date (19 Sept 2014).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cobimetinib treatment was associated with serous retinopathy in patients with BRAF (V600)-mutated melanoma. Retinopathy was generally asymptomatic or mild. Periodic ophthalmologic evaluations at regular intervals and at the manifestation of any visual disturbance are recommended to facilitate early detection and resolution of serous retinopathy while patients are taking cobimetinib. Trial Registration Clinicaltrials.gov (NCT01689519). First received: September 18, 2012.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de la Cruz-Merino</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani 3, 41071, Seville, Spain. lucme12@yahoo.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Guardo</LastName><ForeName>Lorenza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grob</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, Hôpital de la Timone, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venosa</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ospedale Monaldi, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larkin</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Marsden NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McArthur</LastName><ForeName>Grant A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribas</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ascierto</LastName><ForeName>Paolo A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Jeffrey T R</ForeName><Initials>JTR</Initials><AffiliationInfo><Affiliation>Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Escobar</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani 3, 41071, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barteselli</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eng</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Jessie J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uyei</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dréno</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nantes University, Nantes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01689519</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jan 1;372(1):30-9</RefSource><PMID Version="1">25399551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2013 Oct;39(6):664-72</RefSource><PMID Version="1">23434072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Aug;15(9):954-65</RefSource><PMID Version="1">25037139</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Case Rep Ophthalmol Med. 2013;2013:673796</RefSource><PMID Version="1">23555064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2002 Jun 27;417(6892):949-54</RefSource><PMID Version="1">12068308</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Mar 1;19(5):1232-43</RefSource><PMID Version="1">23434733</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Nov 17;353(20):2135-47</RefSource><PMID Version="1">16291983</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Nov 13;371(20):1877-88</RefSource><PMID Version="1">25265492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2015 Aug 1;386(9992):444-51</RefSource><PMID Version="1">26037941</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surv Ophthalmol. 2013 Mar-Apr;58(2):103-26</RefSource><PMID Version="1">23410821</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Jul;25(7):1437-41</RefSource><PMID Version="1">24864047</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eye (Lond). 2015 Aug;29(8):1003-12</RefSource><PMID Version="1">26043707</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Ophthalmol. 2014 Aug;132(8):1005-9</RefSource><PMID Version="1">24852144</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Mol Med. 2009 Jun;23(6):771-7</RefSource><PMID Version="1">19424603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Nov 13;371(20):1867-76</RefSource><PMID Version="1">25265494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2014 Jul;11(7):385-400</RefSource><PMID Version="1">24840079</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods Mol Biol. 2011;686:133-48</RefSource><PMID Version="1">21082369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Aug;13(8):773-81</RefSource><PMID Version="1">22805291</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cobimetinib</Keyword><Keyword MajorTopicYN="N">MEK inhibition</Keyword><Keyword MajorTopicYN="N">Melanoma</Keyword><Keyword MajorTopicYN="N">Serous retinopathy</Keyword><Keyword MajorTopicYN="N">Visual disturbance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28646893</ArticleId><ArticleId IdType="doi">10.1186/s12967-017-1246-0</ArticleId><ArticleId IdType="pii">10.1186/s12967-017-1246-0</ArticleId><ArticleId IdType="pmc">PMC5483259</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000A17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28646893
|texte= Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28646893" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |